WAVERLEY PHARMA INC (WAVE.CA) Fundamental Analysis & Valuation

TSX-V:WAVE • CA94357L1058

Current stock price

0.02 CAD
+0.01 (+33.33%)
Last:

This WAVE.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. WAVE.CA Profitability Analysis

1.1 Basic Checks

  • In the past year WAVE has reported negative net income.
  • WAVE had a negative operating cash flow in the past year.
  • In the past 5 years WAVE always reported negative net income.
  • In the past 5 years WAVE always reported negative operating cash flow.
WAVE.CA Yearly Net Income VS EBIT VS OCF VS FCFWAVE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -500K -1M -1.5M -2M

1.2 Ratios

  • WAVE has a better Return On Assets (-28.81%) than 65.22% of its industry peers.
Industry RankSector Rank
ROA -28.81%
ROE N/A
ROIC N/A
ROA(3y)-101.52%
ROA(5y)-69.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WAVE.CA Yearly ROA, ROE, ROICWAVE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 39.48%, WAVE is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
  • WAVE's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for WAVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.45%
GM growth 5Y60.51%
WAVE.CA Yearly Profit, Operating, Gross MarginsWAVE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. WAVE.CA Health Analysis

2.1 Basic Checks

  • WAVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for WAVE remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, WAVE has about the same amount of shares outstanding.
  • WAVE has a better debt/assets ratio than last year.
WAVE.CA Yearly Shares OutstandingWAVE.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
WAVE.CA Yearly Total Debt VS Total AssetsWAVE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • WAVE has an Altman-Z score of -13.42. This is a bad value and indicates that WAVE is not financially healthy and even has some risk of bankruptcy.
  • WAVE has a Altman-Z score (-13.42) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.42
ROIC/WACCN/A
WACC8.05%
WAVE.CA Yearly LT Debt VS Equity VS FCFWAVE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • WAVE has a Current Ratio of 0.11. This is a bad value and indicates that WAVE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.11, WAVE is not doing good in the industry: 65.22% of the companies in the same industry are doing better.
  • WAVE has a Quick Ratio of 0.11. This is a bad value and indicates that WAVE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • WAVE has a worse Quick ratio (0.04) than 73.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.04
WAVE.CA Yearly Current Assets VS Current LiabilitesWAVE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. WAVE.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 83.45% over the past year.
  • WAVE shows a strong growth in Revenue. In the last year, the Revenue has grown by 2017.58%.
  • The Revenue for WAVE have been decreasing by -16.30% on average. This is quite bad
EPS 1Y (TTM)83.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
Revenue 1Y (TTM)2017.58%
Revenue growth 3Y-35.27%
Revenue growth 5Y-16.3%
Sales Q2Q%1130.8%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WAVE.CA Yearly Revenue VS EstimatesWAVE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

Find the best growth stocksShow best growing peers

0

4. WAVE.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • WAVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WAVE.CA Price Earnings VS Forward Price EarningsWAVE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WAVE.CA Per share dataWAVE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. WAVE.CA Dividend Analysis

5.1 Amount

  • WAVE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

WAVE.CA Fundamentals: All Metrics, Ratios and Statistics

WAVERLEY PHARMA INC

TSX-V:WAVE (3/23/2026, 7:00:00 PM)

0.02

+0.01 (+33.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-25
Earnings (Next)04-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners74.9%
Ins Owner ChangeN/A
Market Cap1.08M
Revenue(TTM)1.51M
Net Income(TTM)-367.10K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.03
BVpS-0.04
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.48%
FCFM N/A
ROA(3y)-101.52%
ROA(5y)-69.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.45%
GM growth 5Y60.51%
F-Score3
Asset Turnover1.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.04
Altman-Z -13.42
F-Score3
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2017.58%
Revenue growth 3Y-35.27%
Revenue growth 5Y-16.3%
Sales Q2Q%1130.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y74.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.35%
OCF growth 3YN/A
OCF growth 5YN/A

WAVERLEY PHARMA INC / WAVE.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of WAVERLEY PHARMA INC (WAVE.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA.


Can you provide the valuation status for WAVERLEY PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to WAVERLEY PHARMA INC (WAVE.CA). This can be considered as Overvalued.


Can you provide the profitability details for WAVERLEY PHARMA INC?

WAVERLEY PHARMA INC (WAVE.CA) has a profitability rating of 2 / 10.


What is the financial health of WAVERLEY PHARMA INC (WAVE.CA) stock?

The financial health rating of WAVERLEY PHARMA INC (WAVE.CA) is 1 / 10.